Drug intelligence / Profile preview

ST-113

Development stage: Preclinical
Lead developer: Stuart Therapeutics
Modality: Peptides

Overview

ST-113 is a synthesized collagen mimetic peptide being investigated as a treatment for open-angle glaucoma, including normal tension glaucoma. It selectively restores damaged helical collagen in the extracellular matrix, aiming to reduce inflammation and restore nerve health by restoring collagen's structural and cell signaling functions within the optic nerve region.

Targets

COL (Collagen type XXI alpha 1 chain)

Beyond the preview

Go deeper on ST-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-113.

Explore the full profile